Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.
Daniel G. Stover, MD
Daniel Stover, MD, is a medical oncologist who specializes in the treatment of breast cancer at The Ohio State Comprehensive Cancer Center and assistant professor in the department of internal medicine at The Ohio State University. He attended medical school and completed his residency at the Vanderbilt University School of Medicine in Nashville, TN, and completed his medical oncology and research fellowships at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.
Articles by Daniel G. Stover, MD
Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.
Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.
Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.